Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.

Next Previous
Trial Profile

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MRD-1
  • Sponsors Novartis

Most Recent Events

  • 29 Dec 2009 Trial acronym MRD-1 identified as reported by ClinicalTrials.gov.
  • 29 Dec 2009 Actual patient number (96) added as reported by ClinicalTrials.gov.
  • 29 Dec 2009 Planned end date (Nov 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top